Pitt-Ohio State Clinical Trials Unit Administrative Supplement

匹兹堡大学病毒学专业实验室将使用来自ThermoFisher和Hologic的EUA批准的检测平台对提供的各种样本（鼻咽拭子、咽拭子和唾液）进行检测，用于检测SARS-CoV-2患者，以提高美国的检测能力。检测量将取决于样本交付和检测试剂盒的可用性。目前的产能最初约为25-50个样本，随着试剂供应链的充足，每天将增加到100-200个样本。俄亥俄州州立大学医学中心的临床实验室正在使用多种PCR和血清学检测平台（例如CDC、DiaSorin、Abbott等）显著提高其检测能力。使用医疗中心的CLIA认证的测试场所，我们建议制定一个协议，以确定，测试和获得从定义的人群谁不是在优先测试的顶级临床病史。

The University of Pittsburgh Virology Specialty Laboratory will test various samples provided (nasopharyngeal swabs, throat swabs, and saliva) using EUA approved testing platforms from ThermoFisher and Hologic for patients testing for SARS-CoV-2 to increase the United States testing capacity. Testing volume will depend on sample delivery and test kit availability. Capacity will initially approximate 25-50 samples today, ramping up to 100-200 per day with a sufficient supply chain for reagents. The Ohio State University Medical Center’s Clinical Laboratories are significantly increasing their testing capacity using multiple platforms for PCR and serologic testing (e.g. CDC, DiaSorin, Abbott to name a few). Using the Medical Center’s CLIA-certified testing venues, we propose to develop a protocol to identify, test and obtain clinical history from defined populations who are not in the top tier for priority testing.